PYC Therapeutics Advances to Multiple-Dose Study of Drug Candidate in Patients with Blinding Eye Disease; Shares Down 4%

MT Newswires Live10-09

PYC Therapeutics (ASX:PYC) said it is advancing to a global multiple ascending dose (MAD) study of its investigational drug candidate PYC-001 in patients with autosomal dominant optic atrophy (ADOA) following the review of the single ascending dose (SAD) study, according to a Thursday filing with the Australian bourse.

The Safety Review Committee reviewed the four-week safety/tolerability data for the third and final patient cohort in the SAD study and confirmed that there are no safety concerns in any of the three doses assessed in the study, the filing said.

ADOA is a blinding eye disease affecting 1 in every 35,000 people.

The phase 1/2 MAD study is expected to begin in the fourth quarter of the year, per the filing.

Shares fell more than 4% in afternoon trade on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574188616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574188616","market":"us","top_or_hot":-1,"title":"PYC Therapeutics Advances to Multiple-Dose Study of Drug Candidate in Patients with Blinding Eye Disease; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said it is advancing to a global multiple ascending dose (MAD) study of its investigational drug candidate PYC-001 in patients with autosomal dominant optic atrophy (ADOA) following the review of the single ascending dose (SAD) study, according to a Thursday filing with the Australian bourse.</p><p>The Safety Review Committee reviewed the four-week safety/tolerability data for the third and final patient cohort in the SAD study and confirmed that there are no safety concerns in any of the three doses assessed in the study, the filing said.</p><p>ADOA is a blinding eye disease affecting 1 in every 35,000 people.</p><p>The phase 1/2 MAD study is expected to begin in the fourth quarter of the year, per the filing.</p><p>Shares fell more than 4% in afternoon trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Advances to Multiple-Dose Study of Drug Candidate in Patients with Blinding Eye Disease; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Advances to Multiple-Dose Study of Drug Candidate in Patients with Blinding Eye Disease; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-09 10:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said it is advancing to a global multiple ascending dose (MAD) study of its investigational drug candidate PYC-001 in patients with autosomal dominant optic atrophy (ADOA) following the review of the single ascending dose (SAD) study, according to a Thursday filing with the Australian bourse.</p><p>The Safety Review Committee reviewed the four-week safety/tolerability data for the third and final patient cohort in the SAD study and confirmed that there are no safety concerns in any of the three doses assessed in the study, the filing said.</p><p>ADOA is a blinding eye disease affecting 1 in every 35,000 people.</p><p>The phase 1/2 MAD study is expected to begin in the fourth quarter of the year, per the filing.</p><p>Shares fell more than 4% in afternoon trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2574188616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574188616","pubTimestamp":1759975861,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics (ASX:PYC) said it is advancing to a global multiple ascending dose (MAD) study of its investigational drug candidate PYC-001 in patients with autosomal dominant optic atrophy (ADOA) f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","PYC.AU":"PYC THERAPEUTICS LTD","BK7064":"综合支持服务","BK4139":"生物科技","LENZ":"Therapeutics","MAD.AU":"MADER GROUP LTD","BK7067":"生物科技"},"translate_title":"PYC Therapeutics在致盲眼病患者中推进候选药物的多剂量研究；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYC.AU":1,"LENZ":1.5,"MAD.AU":1},"content_text":"PYC Therapeutics (ASX:PYC) said it is advancing to a global multiple ascending dose (MAD) study of its investigational drug candidate PYC-001 in patients with autosomal dominant optic atrophy (ADOA) following the review of the single ascending dose (SAD) study, according to a Thursday filing with the Australian bourse.The Safety Review Committee reviewed the four-week safety/tolerability data for the third and final patient cohort in the SAD study and confirmed that there are no safety concerns in any of the three doses assessed in the study, the filing said.ADOA is a blinding eye disease affecting 1 in every 35,000 people.The phase 1/2 MAD study is expected to begin in the fourth quarter of the year, per the filing.Shares fell more than 4% in afternoon trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574188616","isCrawlerRequest":true}